CatalystFDA/Bio

Mirum's Livmarli meets primary goal in phase 3 trial for itch with rare liver diseases

Mirum's Livmarli met its phase 3 primary endpoint in rare liver disease.

What changed

Mirum's Livmarli met its phase 3 primary endpoint in rare liver disease.

Why it matters

Mirum's Livmarli met its phase 3 primary endpoint in rare liver disease. — impact context not separately stored; see What changed.

Sources